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ABSTRAK
Latar belakang: peningkatan nilai minimum inhibitory concentration (MIC) dari bakteri methicillin-resistant 
Staphylocuccus aureus (MRSA) dapat menyebabkan perburukan kondisi klinis pasien khususnya pasien yang 
berada dalam kondisi kritis. Tujuan penelitian ini adalah untuk mengidentifikasi pengaturan dosis vancomycin 
yang paling tepat untuk mengatasi infeksi yang disebabkan oleh MRSA dengan nilai MIC yang tinggi pada 
pasien kritis etnis Thailand. Metode: replikasi sebanyak 10.000 kali terhadap beberapa rejimen dosis vancomycin 
dilakukan dengan menggunakan Monte Carlo simulation. Nilai parameter farmakokinetik vancomycin didapatkan 
dari penelitian yang dilakukan pada pasien etnis Thailand. Setelah simulasi selesai, dihitung nilai probability 
of target attainment (PTA) dan cumulative fraction of response (CFR) dari setiap rejimen dosis vancomycin. 
Risiko terjadinya nefrotoksik juga dihitung dan digunakan sebagai pertimbangan dalam menentukan rejimen 
dosis vancomycin. Hasil: dosis vancomycin yang lebih tinggi, yakni: 3g/hari dan 4g/hari, dibutuhkan untuk 
mencapai nilai PTA 80% jika vancomycin digunakan untuk mengatasi MRSA dengan MIC 1,5mg/L dan 2,0 mg/L, 
secara berturut-turut. Nilai CFR tertinggi, yakni 94,40% dan 93,57%, didapatkan dari rejimen dosis 1g setiap 
6 jam dan 2g setiap 12 jam. Dosis standar vancomycin, yakni 1g setiap 12 jam, dan rejimen dosis dengan total 
3g/hari dapat mencapai CFR 51% dan 73%. Risiko nefrotoksik yang dihasilkan dari dosis rejimen 1,5g setiap 
12 jam dan 2g setiap 12 jam adalah sebesar 26,59% dan 31,20%. Kesimpulan: dosis vancomycin 1,5g setiap 
12 jam dan 2g setiap 12 jam yang diberikan secara intermittent seharusnya diimplementasikan sebagai terapi 
definitif pada pasien yang terinfeksi MRSA dengan MIC 1,5 dan 2,0 mg/dl, secara berturut-turut.
Kata kunci: Vancomycin, pasien kritis, Thai population, Monte Carlo simulation, MIC creep.
ABSTRACT
Background: the shifting of minimum inhibitory concentration (MIC) of methicillin-resistant Staphylocuccus 
aureus (MRSA) strains to the higher value has emerged to worsen clinical outcome to the patients particularly 
critically ill population.  The aim of this study was to identify the most appropriate dosage regimen of vancomycin 
to treat infection caused by MRSA with higher MIC in critically ill Thai population. Methods: 10,000 replications 
of intermittent vancomycin dosage regimens were performed using Monte Carlo simulation. Pharmacokinetic 
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parameters were derived from a population pharmacokinetic study conducted specifically in Thai population. 
The probability of target attainment (PTA) and cumulative fraction of response (CFR) of each dosage regimen 
were calculated. Risk of nephrotoxicity was also calculated and used as a consideration in determining the most 
appropriate dosage regimen of vancomycin. Results: in order to achieve desired PTA > 80% vancomycin at 
higher dosing regimens were needed including 3g/day and 4 g/day for MIC 1.5mg/L and 2.0 mg/L, respectively. 
Highest CFR of 94.40% and 93.57% were from vancomycin 1 g every 6 h and 2 g every 12h. Standard dose 
of vancomycin and total dose of vancomycin 3 g/day provided approximately 51% and 73% CFR. Risk of 
nephrotoxicity afforded by giving 1.5g every 12h and 2g every 12h of vancomycin were 26.59% and 31.20%, 
respectively. Conclusion: the result from this study recommended intermittent dosage regimen 1.5g every 12h 
and 2g every 12h should be implemented as definite antibiotic treatment when considered infection caused by 
MRSA with MIC 1.5 and 2.0 mg/L, respectively.
Keywords: Vancomycin, critically ill, Thai population, Monte Carlo simulation, MIC creep.
INTRODUCTION
Nowadays, there is a greater interest in 
using vancomycin to treat Methicillin Resistant 
Staphylococcus aureus (MRSA) infected 
patients. Several published studies found higher 
risk of treatment failure when vancomycin was 
used to treat susceptible strains with higher 
vancomycin minimum inhibitory concentration 
(MIC) value.1-4 Moreover, there is phenomenon 
called “MIC creep” which is the concern 
of shifting of vancomycin MICs within the 
susceptibility range to MRSA.3 Vancomycin 
dosage adjustment is ultimately needed to achieve 
the desired target of treatment of vancomycin, 
i.e area under the plasma drug concentration and 
time curve at steady-state over 24 hours (AUC0-
24) over MIC (AUC0-24/MIC) of ≥400mg.
hr/L unless otherwise stated.5 Achievement 
of desired target of treatment provided good 
clinical outcome for patients. Moreover, results 
that were derived from in vitro studies revealed 
that achievement to desired AUC0-24/MIC 
value would prevent the development of 
further resistant strains.6,7 However, it is very 
challenging to ensure the achievement of the 
desired target of treatment particularly in the era 
of “MIC Creep” phenomenon because higher 
AUC0-24 is needed to compensate higher value 
of MIC. The most important question is how 
vancomycin dosage regimens should be applied 
in the era of “MIC Creep” phenomenon which is 
ultimately determined by pharmacokinetics (PK) 
parameters of particular population.8-10
One population with deviated vancomycin 
PK parameters is the critically ill patients.11,12 
Critically ill population tend to have larger 
volume of distribution (Vd) and faster clearance 
creatinine (CLcr) compared with non-critically ill 
population.8-12 The different PK parameters might 
be caused by different physiologic condition 
compared with non-critically ill populations and/
or the treatment given to critically ill, such as 
massive fluid treatment.11 Since vancomycin is 
classified as the hydrophilic drug with majority 
elimination process by glomerular filtration 
rate (GFR), thus, the Vd and CLcr are the most 
important PK parameters in determining the 
achievement of desired AUC0-24/MIC. It is 
expected that determining proper vancomycin 
dosing regimen in critical care service becomes 
more challenging for MRSA infection which 
is also proven to be one of the most virulent 
pathogens in intensive care unit (ICU).13,14
Generally, there will be a great risk of 
treatment failure and/or adverse drug reaction 
(ADR) in critically ill patients. Likewise, 
vancomycin has several adverse drug reaction 
profiles, including “Red-man syndrome”, 
thrombocytopenia, neutropenia, ototoxicity, and 
nephrotoxicity. Compared with other adverse 
drug reactions, nephrotoxicity is known as one of 
the most concerning adverse drug reactions since 
it is associated with higher financial burden.15 
In order to minimize nephrotoxicity from 
vancomycin, the trough concentration ≥15 mg/L 
was mostly recommended as the threshold to 
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determine risk of nephrotoxicity for intermittent 
regimens.16-19
In the era of anti-MRSA limitation especially 
in developing countries, the role of vancomycin 
as a first-line therapy in the management of 
“MIC Creep” MRSA becomes more important. 
In Thailand, the limited antibiotics alternative 
for MRSA is a major concern due to none of 
them has been proven to be more effective than 
vancomycin. Additionally, safety profiles also 
limit its use in some patients. This study aimed to 
determine the most appropriate dosage regimen 
of intermittent vancomycin to treat “MIC Creep” 
MRSA infection in critically ill Thai population.
METHODS
Model Construction
A 10,000 trial Monte Carlo simulation was 
performed for each vancomycin regimen (Crystal 
Ball® 2000; Decisioneering Inc., Denver, CO). 
The ratio of AUC0-24/MIC of 400 mg.hr/L was 
set as the target of vancomycin treatment. Age 
was assumed to be a log-Gaussian distribution. 
However, CLcr had been set as uniform 
distribution with defined CLcr value of 60-120 
mL/min. The simulated vancomycin dosage 
regimens were: 1 g every 12 h; 1 g every 8 h; 1 
g every 6 h; that should be infused in 1 h; and 
1.5 g every 12 h; 2 g every 12 h that should be 
infused in 2 h.
The complete final population PK equation 
models of vancomycin for Thai population used 
in present study was derived from a published 
PK vancomycin model among Thai population.20 
It is estimated that more than 30% of critically 
ill patients were recruited to the referenced 
study. The PK models were presented in Table 1 
which revealed good predictive performance for 
critically ill population with the mean prediction 
error of -1.43 (95% CI -5.82 to -2.99) and root 
mean squared prediction error of 12.28 (95% CI 
-1.60 to -26.16). Two compartment model has 
been proven as the best compartment model by 
that PK equation model.
Vancomycin plasma concentration-time 
profile was calculated in 0.25-h time incremental 
until steady state condition had been achieved 
using Oracle Crystall Ball® that was already 
added in the Microsoft Office Excel 2007 edition 
(Microsoft Corporation, Redmond, Washington). 
Concentration of vancomycin at the third day 
was used to calculate AUC0-12 using trapezoidal 
method.
Bacterial Isolates and Susceptibility Testings
The MIC distribution data of vancomycin 
susceptible MRSA strain (MIC <2.0 mg/L) in this 
study was derived from European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
database.21 Data from EUCAST database clearly 
indicated that MIC distribution has been shifted 
to the higher value. There were 0.24%, 60.35%, 
39.11% of MRSA strains with MIC 0.5 mg/L, 1 
mg/L, and 2 mg/L, consecutively, while the rest 
had MIC 4.0 mg/L.
In order to represent the real MRSA MIC 
distribution from hospital in Thailand, this study 
conducted sensitivity analysis by changing the 
proportional of MRSA strains at a certain MIC. 
The best scenario was assumed that all (100%) 
of MRSA strains had MIC 0.5 mg/L. The worst 
scenario was assumed that all (100%) of MRSA 
strains had MIC 2.0 mg/L. There were some 
scenarios implemented in between the best and 
the worst scenario by changing the percentage of 
MRSA strains in particular MIC value.
Model Simulation and Analysis
Result of 10,000 simulation was recorded 
and further analyzed for the achievement of 
probability of target attainment (PTA) and 
cumulative fraction of response (CFR). The 
percentage of PTA was claculated for each MIC 
of 0.5 mg/L, 1.0 mg/L, 1.5 mg/L, and 2.0 mg/L. 
The percentage of PTA in each regimen dosage 
Table 1. Final population PK equation models for Thai 
population.





0.0444 x CLCr 
(mL/min) 35.78%
Volume of central 
compartment (V1; in L)
0.542 x Age 
(years old) 20.93%
Intercompartmental 
clearance (Q; in L/h) 6.95 39.50%
Volume of peripheral 
compartment (V2; in L) 44.20 57.27%
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multiplied by fraction of bacteria in the MIC 
distribution derived from EUCAST database and 
also the case of simulation represented the value 
of CFR.22 This study used the value of PTA and 
CFR>80% as the threshold to define efficacy of 
particular dosage regimen for each MIC value 
of MRSA.
Model Simulation on Renal Function Effect
Each simulated vancomycin dosage regimen 
provided particular trough concentration that was 
used to calculate the risk of nephrotoxicity. The 
trough concentration had been classified into 
several groups based on the referenced study 
which are trough concentration at <10 mg/L, 
10 – 15 mg/L, 15 – 20 mg/L, >20 mg/L.17 The 
nephrotoxicity occurrences were 5%, 21%, 
20%, and 33%, respectively. In order to get 
more detailed figure of trough concentration, 
the present study further classified the trough 
concentration >20 mg/L into 20-35 mg/L and 
>35 mg/L.
Risk of nephrotoxicity in each group 
was calculated by multiplying the proportion 
of achievement of each trough range or the 
plateau concentration with the occurrence of 
nephrotoxicity in that same range. The total risk 
of nephrotoxicity was determined by adding the 
risk of nephrotoxicity in each range of trough or 
plateau concentration. 
RESULTS
Our study demonstrated that at MIC of 0.5 
mg/L, any vancomycin intermittent dosage 
regimens provided 100.00% PTA. However, 
MIC of 1.0 mg/L only provided 84.41% PTA 
when administered standard dose of vancomycin, 
defined as 1 g every 12 hours or total dose of 
vancomycin 2 g/day. Likewise, vancomycin 
3 g/day and 4 g/day were needed to achieve 
PTA of >80% for higher MIC of 1.5 mg/L and 
2 mg/L, respectively. Figure 1 presented the 
PTA of several vancomycin intermittent dosage 
regimens against each MIC value of MRSA. 
Figure 2 portrayed the comparison between 
percentage of PTA of each intermittent dosage 
regimen and the cumulative percentage of MIC 
distribution of MRSA strain. Our finding also 
indicated that at MIC of 2 mg/L, we needed the 
intermittent dosage regimen of 4 g/day, either 
given as 1 g every 6 hours or 2 g every 12 hours, 
to achieve MIC90.
Results from the PTA calculation were used 
to calculate the CFR. Highest CFR of 94.40% and 
93.57% were from vancomycin 1 g every 6 h and 
2 g every 12h, respectively while standard dose 
of vancomycin and total dose of vancomycin 3 
g/day provided approximately 51% and 73% 
CFR, respectively (Figure 3). Table 2 presented 
the sensitivity analysis of intermittent dosage 
regimens of vancomycin. The analysis showed 
that, if 50% of MRSA population had MIC value 
>1.0 mg/L, the standard dosage regimen will 
only grant CFR <50 %. Intermittent infusion with 
dosage regimen of 3 g/day was not optimal when 
used with MIC 2.0 mg/L while the intermittent 
dosage regimen 4 g/day could maintain CFR 
>80% for all population at the same MIC.
Trough concentrations of each dosing regimen 
were presented in Figure 4. Approximately 17% 
of standard dose regimen confered trough at 5-10 
Table 2. The percentage of CFR achievement for intermittent dosage regimens with different proportion of MIC distribution.












0.5 1.0 1.5 2.0 CFR (%) CFR (%) CFR (%) CFR (%) CFR (%)
100 0 0 0 100.00 100.00 100.00 100.00 100.00
50 50 0 0 92.20 100.00 100.00 100.00 100.00
0 100 0 0 84.41 100.00 100.00 100.00 100.00
0 50 50 0 49.90 92.66 100.00 92.16 100.00
0 50 25 25 46.05 79.75 96.61 79.28 96.08
0 50 0 50 42.20 66.84 93.22 66.39 92.16
0 0 100 0 15.39 85.33 100.00 84.33 100.00
0 0 50 50 7.69 59.50 93.22 58.56 92.17
0 0 0 100 0.00 33.68 86.44 32.79 84.33
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Figure 1. Percentage of PTA achievement of intermittent dosage regimens.
Figure 2. Comparison of percentage PTA achievement of intermittent dosage 
regimens and cumulative MIC distribution of MRSA strain.
Figure 3. Percentage of CFR achievement of intermittent dosage regimens.
Vol 51 • Number 1 • January 2019      Optimization of intermittent Vancomycin dosage regimens for Thai critically ill
15
mg/L, while the highest trough concentration, 
i.e:>35 mg/L, was only afforded by total daily 
dose 4 g, either given as 1 g every 6 hours 
(34.78%) or 2 g every 12 hours (18.68%). Total 
risk of nephrotoxicity for each intermittent 
dosage regimen was presented in Figure 5. 
Standard dose of vancomycin afforded the lowest 
risk of nephrotoxicity (18.27%). The highest 
risk of nephrotoxicity was afforded from dosage 
regimen 1 g every 6 hours (32.96%). 
DISCUSSION
The present simulation study was performed 
to assist clinicians optimizing vancomycin in the 
era of MIC creep. The lowest total daily dose 
simulated in our study was 1 g every 12 hours can 
afford desired PTA >80% for MRSA infection 
with MIC 0.5 mg/L and 1.0 mg/L. Our finding 
was supported by Kuti, et al and Patel, et al.23,24 
The similar results were obtained for both MIC 
0.5 mg/L and 1.0 mg/L. These findings suggested 
Figure 4. Percentage of particular trough concentration achievement of intermittent dosage 
regimens.
Figure 5. Risk of nephrotoxicity of several intermittent dosage regimens with concomitantly 
given other nephrotoxic agents.
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the ramification that no further advantages 
could be granted by giving more intensive 
vancomycin dosage regimens, either increased 
the vancomycin dose or given more frequently 
particular dose of vancomycin to treat infection 
caused by MRSA with MIC ≤1 mg/L.
However, standard intermittent dosage 
regimen will not achieve the desired PTA when 
used to treat MRSA with MIC 1.5 mg/L. To our 
knowledge, this study was the only study that 
analyzed the achievement of PTA for treating 
MRSA with MIC 1.5 mg/L. Intermittent dosage 
regimens with total daily dose of 3 g would be 
best recommendation to achieve PTA >80% to 
treat MRSA with MIC 1.5 mg/L. While MRSA 
with MIC 2.0 mg/L, finding from present study 
was in accordance with the findings of study 
conducted by Kuti, et al23 and Patel, et al24 to 
support the use of vancomycin intermittent 
dosage regimens with total daily dose 4 g to 
achieve the desired PTA value.
All PTA in intermittent dosage regimens 
were at steady state condition as recommended 
by the Infectious Diseases Society of America 
(IDSA) guideline.5 This study also presented 
analysis of PTA for each intermittent dosage 
regimen against percent cumulative MIC 
distribution of MRSA to present the MIC50 and 
MIC90 of MRSA strain (Figure 2). Based on 
cumulative MIC distribution, 50% of MRSA had 
MIC ≤1 mg/L. Standard dosage regimen would 
be able to achieve MIC50. It was not required 
more intensive vancomycin dosage regimens to 
achieve MIC50. However, to achieve MIC90, 
more intensive dosage regimen was needed. 
Ninety percent of MRSA strain in EUCAST 
database had an MIC between 1.5 mg/L to 2.0 
mg/L. Only dosage regimens with a total daily 
dose 4 g, either given as dosage regimen 1 g 
every 6 hours or 2 g every 12 hours, could afford 
MIC90 based on this MIC distribution data.
Specific dosage regimen afforded more 
favourable PTA than others in certain MIC. In 
general, the value of PTA was very helpful to 
guide the health care professional in determining 
the dose of vancomycin for definite antibiotic 
treatment after MIC disclosed. However, as 
empiric antibiotic treatment, it is inconceivable 
to retrieve MIC value at the time of treatment 
initiation; thus PTA might not be advantageous. 
In contrast, the CFR would be more beneficial 
with regards to estimation of probability to be 
success when using vancomycin intermittent 
dosage regimen in random MIC value of 
susceptible MRSA strain.
The present study revealed that the most 
intensive intermittent dosage regimens, either 
given as 2 g every 12 hours or 1 g every 6 
hours, were needed to achieve desired CFR 
value. Finding of present study was consistent 
with study from del Mar Fernandez de Gatta, 
et al.25 conducted in patients with malignant 
haematological disease and study from Revilla, 
et al.12 conducted in ICU patients. The MIC 
distribution of Staphylococcus aureus in their 
studies were similar to the EUCAST database 
which most MIC value was 1.0 mg/L. They 
found that vancomycin with total daily dose 2 
g provided the lowest CFR achievement, while 
total daily dose 4 g achieved the desired CFR 
value. Unfortunately, the authors did not clearly 
state the method of vancomycin administration 
whether given as the intermittent infusion or 
continuous infusion.
Results from our sensitivity analysis for 
intermittent dosage regimens pointed out several 
important findings. Intermittent standard dosage 
regimen could afford CFR >80% when MRSA 
strain had MIC <1.0mg/L. In the setting where 
most of identified MRSA strain had MIC >1.0 
mg/L, higher total daily dose of intermittent 
was ultimately needed. Total daily dose of 3 
g is suggested to achieve CFR >80% when no 
MRSA with MIC 2.0 mg/L. Nonetheless, if there 
are 25% of MRSA with MIC 2.0 mg/L, the CFR 
achievement of intermittent dosage regimen of 4 
g/day would be the best option to achieve optimal 
CFR. Lastly, if all identified MRSA strain (100%) 
had MIC 2.0 mg/L, the 84.33% PTA could be 
afforded by intermittent dosage regimens 4 g/day.
Our sensitivity analysis emphasizing the 
used of higher dose of vancomycin in settings 
where MRSA with MIC >1.0 mg/L. Canut, et 
al26 conducted a study in 3 different European 
countries, including: Belgium, United Kingdom/
Ireland, and Spain, and each country had different 
profile of MIC distribution. There were less than 
3% and almost 20% of MIC 2.0 mg/L in Spain 
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and United Kingdom/Ireland, respectively while 
all MRSA in Belgium had MIC <1.0 mg/L. 
Vancomycin at least 1 g every 8 hours or 2g every 
12 hours were needed to achieve CFR >90% in 
Spain and United Kingdom/Ireland, respectively. 
Our sensitivity analysis also recommended 
vancomycin with total daily dose 4 g, either 1 
g every 6 hours or 2 g every 12 hours, in Thai 
settings where approximately 25% of MRSA had 
MIC 2.0 mg/L. 
With regards to risk of nephrotoxicity, 
intermittent dosage regimens presented in our 
study had similar nephrotoxicity conducted in 
Patel, et al where four dosage regimens simulated 
which were: 500mg every 12 hours, 1 g every 
12 hours, 1.5 g every 12 hours, and 2 g every 12 
hours.24 The occurrences of the nephrotoxicity 
for each dosage regimen were 10%, 16%, 
25%, and 34%, respectively. As a result, more 
aggressive dosing regimens are more likely to 
decline patient’s renal function.
Beside several important findings were 
elucidated from the present study, the authors 
also acknowledged several limitations. First 
limitation was the PTA and risk of nephrotoxicity 
might be overestimated as a prediction for 
empirical treatment because the population 
PK equation models were measured after 
multiple doses of vancomycin administration. 
Moreover, superimposed method applied to 
calculate the vancomycin concentration at 
steady state condition might also contribute to 
the overestimated results. Second limitation 
was the assumption that the simulated patients 
had no renal insufficiency. Therefore, our 
recommendations could not be applied to all Thai 
critically ill patients. Further study is necessary to 
determine the best dosage regimen for critically 
ill population with advanced renal impairment. 
Final limitation was related with another MRSA 
virulence factors such as biofilm production. 
This might need different desired PK-PD indices 
when vancomycin is intended to overcome 
MRSA strain. Further investigations are in need 
whether desired AUC0-24/MIC ≥400 mg.hr/L 
could also effectively use as the surrogate marker 
of vancomycin efficacy for MRSA strain with 
biofilm production.
CONCLUSION 
Standard dose of vancomycin could 
potentially not achieve the desired PK/PD 
indices if it was used to treat MRSA infection 
with “MIC Creep” phenomenon. Instead, 
vancomycin 3 g/day, either given as 1 g every 8 
hours or 1.5 g every 12 hours, might be the best 
recommended empirical dose of vancomycin 
in the setting where MRSA has MIC 1.5 mg/L. 
The best dosage regimen for each setting should 
have a balance between high achievement of 
efficacy and acceptable risk of nephrotoxicity. 
However, it was difficult to make a threshold 
of the acceptable risk of nephrotoxicity for 
particular vancomycin dosage regimen. No 
consensus of the threshold of the acceptable risk 
of nephrotoxicity could be found. Further studies 
are needed to verify the conclusions drawn from 
these simulations.
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